ArticleJournal of gastroenterology and hepatology2026
Cyclocarya paliurus Polysaccharides Attenuate High-Fat Diet-Induced Metabolic Dysfunction via Gut Microbiota Remodeling.
Article in Journal of gastroenterology and hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Microbiota Transfer Supports Contribution, Not Dependence, in the Metabolic Effects of Cyclocarya paliurus Polysaccharides.Journal of gastroenterology and hepatology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
BACKGROUND AND
aimAlterations in gut microbiota composition are closely associated with obesity and metabolic disorders. Cyclocarya paliurus polysaccharides (CCPP) have been shown to improve lipid metabolism and modulate the gut microbiota; however, mechanistic evidence remains limited and may vary depending on preparation methods. This study investigated whether a crude polysaccharide-enriched Cyclocarya paliurus preparation alleviates high-fat diet-induced metabolic dysfunction and is associated with gut microbiota remodeling.
methodsMale C57BL/6 J mice were randomized into three groups: normal diet (ND), high-fat diet (HFD), and HFD supplemented with CCPP for 12 weeks. Serum metabolic parameters were measured; intestinal inflammatory cytokine transcripts were assessed by qRT-PCR; and cecal microbiota composition was analyzed by 16S rRNA gene sequencing. Additionally, fecal microbiota transplantation (FMT) was performed by transferring microbiota from CCPP-treated donors to antibiotic-pretreated HFD-induced recipients for 8 weeks.
resultsCCPP attenuated HFD-induced body weight gain and reduced subcutaneous and visceral adipose tissue mass. CCPP significantly improved serum total cholesterol and low-density lipoprotein cholesterol (LDL-C) and reduced fasting glucose. Cecal 16S rRNA gene profiling showed that CCPP reshaped the gut dysbiosis associated with a HFD and enriched microbial taxa that are commonly linked to carbohydrate fermentation. These taxa specifically include Lachnospiraceae-related microbial taxa and Ileibacterium. Importantly, FMT from CCPP-treated donors recapitulated these metabolic improvements, confirming that the benefits of CCPP were microbiota-dependent.
conclusionCCPP mitigates obesity and metabolic dysfunction by remodeling the gut microbiota, particularly by enriching short-chain fatty acid-producing taxa. These findings highlight CCPP as a potential microbiota-targeted therapeutic agent for metabolic disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.